YU-SHAN HUANGCheng C.-Y.Liou B.-H.Lu P.-L.Cheng S.-H.Lee Y.-T.Liu C.-E.HSIN-YUN SUNYang C.-J.Tang H.-J.Lin S.-P.Ho M.-W.Huang S.-H.Tsai H.-C.Lee C.-H.CHIEN-CHING HUNGTaiwan HIV Study Group2021-08-202021-08-2020211944-7884https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102221589&doi=10.1097%2fQAI.0000000000002589&partnerID=40&md5=82faf108c7700ebd0c91fa75d7dbce2bhttps://scholars.lib.ntu.edu.tw/handle/123456789/578639BACKGROUND: The efficacy and safety of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/hepatit[SDGs]SDG3journal article10.1097/QAI.0000000000002589332732142-s2.0-85102221589